|Bid||4.35 x 4400|
|Ask||4.38 x 200|
|Day's Range||4.32 - 4.46|
|52 Week Range||0.04 - 30.41|
|PE Ratio (TTM)||-0.38|
|Earnings Date||May 4, 2017 - May 8, 2017|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||8.00|
ST. PAUL, Minn., July 20, 2017 /PRNewswire/ -- EnteroMedics Inc. (ETRM), a developer of minimally invasive medical devices to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced the receipt of a European Patent Certificate. The Company was granted Patent number 2254659 titled "Treatment of excess weight by neural downregulation in combination with compositions." The patent pertains to EU protection of a system for combination therapy and corresponds with the Company's US intellectual property.
ST. PAUL, Minn., June 28, 2017 /PRNewswire/ -- EnteroMedics Inc. (ETRM), the developer of medical devices to treat obesity, metabolic diseases, and other obesity-related comorbidities, announced today the launch of the vBloc Now program. The program provides qualified patients access to vBloc® Therapy at a reduced cost in partnership with select bariatric and weight loss centers across the United States. "We've repeatedly stated that our goal remains broad coverage and reimbursement for vBloc Therapy," said Dan Gladney, EnteroMedics President, Chief Executive Officer, and Chairman of the Board.
ST. PAUL, Minn., June 26, 2017 /PRNewswire/ -- EnteroMedics Inc. (ETRM), the developer of medical devices to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced that the Company will join the Russell Microcap® Index effective after the U.S. market opens today. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings and style attributes. "EnteroMedics is very pleased to be added to such a widely referenced index," said Dan Gladney, EnteroMedics President, Chief Executive Officer and Chairman of the Board.